{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T23:54:16Z","timestamp":1788652456748,"version":"build-2803163510"},"reference-count":72,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T00:00:00Z","timestamp":1509321600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>This is an overview of the cutaneous porphyrias. It is a narrative review based on the published literature and my personal experience; it is not based on a formal systematic search of the literature. The cutaneous porphyrias are a diverse group of conditions due to inherited or acquired enzyme defects in the porphyrin\u2013haem biosynthetic pathway. All the cutaneous porphyrias can have (either as a consequence of the porphyria or as part of the cause of the porphyria) involvement of other organs as well as the skin. The single commonest cutaneous porphyria in most parts of the world is acquired porphyria cutanea tarda, which is usually due to chronic liver disease and liver iron overload. The next most common cutaneous porphyria, erythropoietic protoporphyria, is an inherited disorder in which the accumulation of bile-excreted protoporphyrin can cause gallstones and, rarely, liver disease. Some of the porphyrias that cause blistering (usually bullae) and fragility (clinically and histologically identical to porphyria cutanea tarda) can also be associated with acute neurovisceral porphyria attacks, particularly variegate porphyria and hereditary coproporphyria. Management of porphyria cutanea tarda mainly consists of visible-light photoprotection measures while awaiting the effects of treating the underlying liver disease (if possible) and treatments to reduce serum iron and porphyrin levels. In erythropoietic protoporphyria, the underlying cause can be resolved only with a bone marrow transplant (which is rarely justifiable in this condition), so management consists particularly of visible-light photoprotection and, in some countries, narrowband ultraviolet B phototherapy. Afamelanotide is a promising and newly available treatment for erythropoietic protoporphyria and has been approved in Europe since 2014.<\/ns4:p>","DOI":"10.12688\/f1000research.10101.1","type":"journal-article","created":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T11:15:05Z","timestamp":1509362105000},"page":"1906","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["An overview of the cutaneous porphyrias"],"prefix":"10.12688","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4732-071X","authenticated-orcid":false,"given":"Robert","family":"Dawe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2017,10,30]]},"reference":[{"key":"ref-1","first-page":"60.1-60.20","article-title":"Chapter 60: Cutaneous Porphyrias.","author":"R Sarkany","year":"2017"},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"106-112","DOI":"10.1201\/b15138-19","article-title":"The Cutaneous Porphyrias","author":"R Dawe","year":"2006"},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"59-60","DOI":"10.1111\/j.1600-0781.2009.00394.x","article-title":"Prevalences of chronic photodermatoses in Scotland.","volume":"25","author":"R Dawe","year":"2009","journal-title":"Photodermatol Photoimmunol Photomed."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"183-90","DOI":"10.1111\/j.1749-6632.1987.tb48773.x","article-title":"Turkish epidemic hexachlorobenzene porphyria. A 30-year study.","volume":"514","author":"H Peters","year":"1987","journal-title":"Ann N Y Acad Sci."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"R10","DOI":"10.1186\/ar2117","article-title":"Early onset pauciarticular arthritis is the major risk factor for naproxen-induced pseudoporphyria in juvenile idiopathic arthritis.","volume":"9","author":"S Sch\u00e4d","year":"2007","journal-title":"Arthritis Res Ther."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"188-98","DOI":"10.1177\/0004563216667965","article-title":"Best practice guidelines on first-line laboratory testing for porphyria.","volume":"54","author":"J Woolf","year":"2017","journal-title":"Ann Clin Biochem."},{"key":"ref-7","first-page":"1138-9","article-title":"Erythropoietic protoporphyria in Denmark: demographic, biochemical and genetic characteristics.","volume":"5","author":"E Erlandsen","year":"2011","journal-title":"Br J Dermatol."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"464-6","DOI":"10.1111\/j.1365-2133.2006.07318.x","article-title":"Acquired erythropoietic protoporphyria as a result of myelodysplasia causing loss of chromosome 18.","volume":"155","author":"R Sarkany","year":"2006","journal-title":"Br J Dermatol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"439-43","DOI":"10.1038\/jid.1963.138","article-title":"Immunologic and Biophysical Studies in Solar Urticaria.","volume":"41","author":"L Harber","year":"1963","journal-title":"J Invest Dermatol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"448-51","DOI":"10.1016\/S0140-6736(61)92427-8","article-title":"Erythropoietic protoporphyria. A new porphyria syndrome with solar urticaria due to protoporphyrinaemia.","volume":"2","author":"I Magnus","year":"1961","journal-title":"Lancet."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"574-81","DOI":"10.1111\/j.1365-2133.2006.07472.x","article-title":"Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life.","volume":"155","author":"S Holme","year":"2006","journal-title":"Br J Dermatol."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"599-605","DOI":"10.1038\/jid.2008.272","article-title":"Seasonal palmar keratoderma in erythropoietic protoporphyria indicates autosomal recessive inheritance.","volume":"129","author":"S Holme","year":"2009","journal-title":"J Invest Dermatol."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"2-14","DOI":"10.1086\/498620","article-title":"Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria.","volume":"78","author":"L Gouya","year":"2006","journal-title":"Am J Hum Genet."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"27-8","DOI":"10.1038\/ng809","article-title":"The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH.","volume":"30","author":"L Gouya","year":"2002","journal-title":"Nat Genet."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"4108-10","DOI":"10.1182\/blood-2007-04-088120","article-title":"Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria.","volume":"110","author":"S Holme","year":"2007","journal-title":"Blood."},{"key":"ref-16","article-title":"Erythropoietic protoporphyria","author":"H Baart de la Faille","year":"1975"},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"130-2","DOI":"10.1182\/blood-2015-05-646737","article-title":"Iron and erythropoietic porphyrias.","volume":"126","author":"E Minder","year":"2015","journal-title":"Blood."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"739-48","DOI":"10.1136\/gut.2006.097576","article-title":"Liver disease in erythropoietic protoporphyria: insights and implications for management.","volume":"83","author":"A Anstey","year":"2007","journal-title":"Postgrad Med J."},{"key":"ref-19","first-page":"1009-18","article-title":"Liver disease in erythropoietic protoporphyria: insights and implications for management.","volume":"56","author":"A Anstey","year":"2007","journal-title":"Gut."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"789-94","DOI":"10.1046\/j.1365-2133.2001.04429.x","article-title":"New sunscreens confer improved protection for photosensitive patients in the blue light region.","volume":"145","author":"H Moseley","year":"2001","journal-title":"Br J Dermatol."},{"key":"ref-21","first-page":"84-97","article-title":"A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria.","volume":"55","author":"E Minder","year":"2009","journal-title":"Cell Mol Biol (Noisy-le-grand)."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"663-8","DOI":"10.1111\/j.1365-2133.1977.tb14274.x","article-title":"The treatment of erythropoietic protoporphyria. Experience with beta-carotene.","volume":"97","author":"S Zaynoun","year":"1977","journal-title":"Br J Dermatol."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"1229-32","DOI":"10.1001\/archderm.1977.01640090077011","article-title":"Beta carotene therapy for erythropoietic protoporphyria and other photosensitivity diseases.","volume":"113","author":"M Mathews-Roth","year":"1977","journal-title":"Arch Dermatol."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"655-62","DOI":"10.1111\/j.1365-2133.1977.tb14273.x","article-title":"The long term treatment with beta-carotene in erythropoietic protoporphyria: a controlled trial.","volume":"97","author":"M Corbett","year":"1977","journal-title":"Br J Dermatol."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"389-94","DOI":"10.1159\/000252070","article-title":"-Carotene as a treatment for photohypersensitivity due to erythropoietic protoporphyria.","volume":"145","author":"H Baart de la Faille","year":"1972","journal-title":"Dermatologica."},{"key":"ref-26","first-page":"245-9","article-title":"Protoporphyrin photosensitivity cannot be attenuated by oral N-acetylcysteine.","volume":"9","author":"J Bijlmer-Iest","year":"1992\u20131993","journal-title":"Photodermatol Photoimmunol Photomed."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"27-30","DOI":"10.1111\/j.1600-0781.1996.tb00240.x","article-title":"A double-blind, placebo-controlled, crossover trial of oral vitamin C in erythropoietic protoporphyria.","volume":"12","author":"M Boffa","year":"1996","journal-title":"Photodermatol Photoimmunol Photomed."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"809-15","DOI":"10.1111\/j.1365-2133.1990.tb06270.x","article-title":"Inhibition of photosensitivity in erythropoietic protoporphyria with terfenadine.","volume":"122","author":"P Farr","year":"1990","journal-title":"Br J Dermatol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"956-63","DOI":"10.1111\/j.1365-2133.1995.tb16955.x","article-title":"Narrow-band UVB (TL-01) phototherapy: an effective preventative treatment for the photodermatoses.","volume":"132","author":"P Collins","year":"1995","journal-title":"Br J Dermatol."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"987-8","DOI":"10.1111\/bjd.12714","article-title":"Narrowband ultraviolet B phototherapy in erythropoietic protoporphyria: case series.","volume":"170","author":"M Sivaramakrishnan","year":"2014","journal-title":"Br J Dermatol."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"179-82","DOI":"10.1111\/j.1440-0960.1998.tb01278.x","article-title":"Erythropoietic protoporphyria treated with narrow-band (TL-01) UVB phototherapy.","volume":"39","author":"L Warren","year":"1998","journal-title":"Australas J Dermatol."},{"key":"ref-32","doi-asserted-by":"crossref","first-page":"247-51","DOI":"10.2340\/00015555-0434","article-title":"Treatment of chronic urticaria with narrowband ultraviolet B phototherapy: a randomized controlled trial.","volume":"88","author":"B Engin","year":"2008","journal-title":"Acta Derm Venereol."},{"key":"ref-33","first-page":"671-85","article-title":"Mechanisms of phototoxicity in porphyria cutanea tarda and erythropoietic protoporphyria.","volume":"46","author":"H Lim","year":"1989","journal-title":"Immunol Ser."},{"key":"ref-34","first-page":"281-6","article-title":"Differential effects of protoporphyrin and uroporphyrin on murine mast cells.","volume":"88","author":"H Lim","year":"1987","journal-title":"J Invest Dermatol."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"1434-9","DOI":"10.1111\/j.1751-1097.2009.00595.x","article-title":"Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone.","volume":"85","author":"J Harms","year":"2009","journal-title":"Photochem Photobiol."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"1601-12","DOI":"10.1111\/bjd.13598","article-title":"Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.","volume":"172","author":"G Biolcati","year":"2015","journal-title":"Br J Dermatol."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"48-59","DOI":"10.1056\/NEJMoa1411481","article-title":"Afamelanotide for Erythropoietic Protoporphyria.","volume":"373","author":"J Langendonk","year":"2015","journal-title":"N Engl J Med."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"768-75","DOI":"10.1111\/bjd.14600","article-title":"Influence of meteorological data on sun tolerance in patients with erythropoietic protoporphyria in France.","volume":"175","author":"S de Bataille","year":"2016","journal-title":"Br J Dermatol."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"1258-61","DOI":"10.1001\/jamadermatol.2016.2303","article-title":"Novel Treatment Using Cimetidine for Erythropoietic Protoporphyria in Children.","volume":"152","author":"J Tu","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref-40","first-page":"811-2","article-title":"Cimetidine in erythropoietic protoporphyria.","volume":"89","author":"K Tanigawa","year":"1994","journal-title":"Am J Gastroenterol."},{"key":"ref-41","first-page":"1465-6","article-title":"Cimetidine reduces erythrocyte protoporphyrin in erythropoietic protoporphyria.","volume":"88","author":"S Yamamoto","year":"1993","journal-title":"Am J Gastroenterol."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/jamadermatol.2016.4049","article-title":"Insufficient Evidence of Cimetidine Benefit in Protoporphyria.","volume":"153","author":"J Langendonk","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"224-8","DOI":"10.1159\/000249258","article-title":"Solar urticaria: a case with good therapeutic response to cimetidine.","volume":"173","author":"Y Tokura","year":"1986","journal-title":"Dermatologica."},{"key":"ref-44","first-page":"39-48","article-title":"Pathogenesis and therapy of liver disease in protoporphyria.","volume":"52","author":"J Bloomer","year":"1979","journal-title":"Yale J Biol Med."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"83-8","DOI":"10.3350\/kjhep.2010.16.1.83","article-title":"Cholestyramine resin for erythropoietic protoporphyria with severe hepatic disease: a case report.","volume":"16","author":"D Yoo","year":"2010","journal-title":"Korean J Hepatol."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"1383-4","DOI":"10.1016\/j.jaad.2012.02.006","article-title":"Oral cholestyramine is not an effective treatment for uncomplicated erythropoietic protoporphyria.","volume":"67","author":"A Tewari","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"1021-6","DOI":"10.1002\/lt.22341","article-title":"Liver transplantation for erythropoietic protoporphyria in Europe.","volume":"17","author":"S Wahlin","year":"2011","journal-title":"Liver Transpl."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"393-4","DOI":"10.1038\/bmt.2009.132","article-title":"The role for BMT in erythropoietic protoporphyria.","volume":"45","author":"S Wahlin","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"1340-6","DOI":"10.1002\/lt.21527","article-title":"Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria.","volume":"14","author":"S Wahlin","year":"2008","journal-title":"Liver Transpl."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"642-6","DOI":"10.1111\/j.1365-2133.2010.09631.x","article-title":"Molecular epidemiology of erythropoietic protoporphyria in the U.K.","volume":"162","author":"S Whatley","year":"2010","journal-title":"Br J Dermatol."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"482-4","DOI":"10.1111\/bjh.13612","article-title":"X-linked protoporphyria: Iron supplementation improves protoporphyrin overload, liver damage and anaemia.","volume":"173","author":"C Landefeld","year":"2016","journal-title":"Br J Haematol."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"S31-9","DOI":"10.1038\/modpathol.3800715","article-title":"Iron overload syndromes and the liver.","author":"K Batts","year":"2007","journal-title":"Mod Pathol."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"271-7","DOI":"10.1097\/00125817-200009000-00001","article-title":"Contribution of different HFE genotypes to iron overload disease: a pooled analysis.","volume":"2","author":"W Burke","year":"2000","journal-title":"Genet Med."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"643-4","DOI":"10.1016\/S0022-5347(17)57310-3","article-title":"Estrogen-induced porphyria cutanea tarda complicating treatment of prostatic carcinoma.","volume":"120","author":"V Weimar","year":"1978","journal-title":"J Urol."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"590-1","DOI":"10.1046\/j.1365-2133.1999.03076.x","article-title":"Porphyria cutanea tarda presenting as solar urticaria.","volume":"141","author":"R Dawe","year":"1999","journal-title":"Br J Dermatol."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"29-57","DOI":"10.1093\/oxfordjournals.qjmed.a067102","article-title":"Porphyria and photosensitivity.","volume":"36","author":"C Rimington","year":"1967","journal-title":"Q J Med."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"745-50","DOI":"10.1111\/j.1365-2133.1985.tb02411.x","article-title":"A case of porphyria cutanea tarda with experimental light urticaria.","volume":"113","author":"M Ichihashi","year":"1985","journal-title":"Br J Dermatol."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"448-52","DOI":"10.1007\/s00105-002-0448-3","article-title":"[Pansclerotic porphyria cutanea tarda after chronic exposure to organic solvents].","volume":"54","author":"T Karamfilov","year":"2003","journal-title":"Hautarzt."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"730-6","DOI":"10.1002\/hep.510310325","article-title":"Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial.","volume":"31","author":"R Fontana","year":"2000","journal-title":"Hepatology."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"16-8","DOI":"10.1111\/dth.12024","article-title":"Desferrioxamine treatment of porphyria cutanea tarda in a patient with HIV and chronic renal failure.","volume":"27","author":"P Vasconcelos","year":"2014","journal-title":"Dermatol Ther."},{"key":"ref-61","first-page":"63-9","article-title":"The cutaneous porphyrias.","volume":"9","author":"G Elder","year":"1990","journal-title":"Semin Dermatol."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"527-38","DOI":"10.1111\/bjh.14459","article-title":"Update review of the acute porphyrias.","volume":"176","author":"P Stein","year":"2017","journal-title":"Br J Haematol."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"543-7","DOI":"10.1001\/archderm.1980.01640290053010","article-title":"A plasma porphyrin fluorescence marker for variegate porphyria.","volume":"116","author":"M Poh-Fitzpatrick","year":"1980","journal-title":"Arch Dermatol."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"261-5","DOI":"10.1111\/j.1365-2133.2011.10606.x","article-title":"Extended haplotype studies in South African and Dutch variegate porphyria families carrying the recurrent p.R59W mutation confirm a common ancestry.","volume":"166","author":"A van Tuyll van Serooskerken","year":"2012","journal-title":"Br J Dermatol."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"204-16","DOI":"10.1177\/0004563212473278","article-title":"Role of genetic testing in the management of patients with inherited porphyria and their families.","volume":"50","author":"S Whatley","year":"2013","journal-title":"Ann Clin Biochem."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"500-6","DOI":"10.1016\/0016-5085(93)90726-S","article-title":"Tin protoporphyrin prolongs the biochemical remission produced by heme arginate in acute hepatic porphyria.","volume":"105","author":"S Dover","year":"1993","journal-title":"Gastroenterology."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0140-6736(91)90411-H","article-title":"Haem-arginate plus tin-protoporphyrin for acute hepatic porphyria.","volume":"338","author":"S Dover","year":"1991","journal-title":"Lancet."},{"key":"ref-68","doi-asserted-by":"publisher","first-page":"901-13","DOI":"10.1111\/j.1365-2133.2012.11160.x","article-title":"Congenital erythropoietic porphyria: a single-observer clinical study of 29 cases.","volume":"167","author":"R Katugampola","year":"2012","journal-title":"Br J Dermatol."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"491-7","DOI":"10.1111\/ejh.12452","article-title":"Congenital erythropoietic porphyria linked to GATA1-R216W mutation: challenges for diagnosis.","volume":"94","author":"E Di Pierro","year":"2015","journal-title":"Eur J Haematol."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"1346-50","DOI":"10.1111\/bjd.14675","article-title":"Late-onset cutaneous porphyria in a patient heterozygous for a uroporphyrinogen III synthase gene mutation.","volume":"175","author":"P Aguilera","year":"2016","journal-title":"Br J Dermatol."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"888-900","DOI":"10.1111\/j.1365-2133.2012.11154.x","article-title":"A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases.","volume":"167","author":"R Katugampola","year":"2012","journal-title":"Br J Dermatol."},{"key":"ref-72","doi-asserted-by":"publisher","first-page":"781-6","DOI":"10.1136\/pgmj.69.816.781","article-title":"Homozygous variegate porphyria: an evolving clinical syndrome.","volume":"69","author":"R Hift","year":"1993","journal-title":"Postgrad Med J."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/6-1906\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/6-1906\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/6-1906\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T19:11:03Z","timestamp":1693163463000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/6-1906\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,30]]},"references-count":72,"URL":"https:\/\/doi.org\/10.12688\/f1000research.10101.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.10882.r27167","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.10882.r27166","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,30]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/6-1906\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.10882.r27166, Henry Lim, Department of Dermatology, Henry Ford Hospital, Detroit, USA, Detroit, Michigan, USA, 30 Oct 2017, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-1906\/v1#referee-response-27166","order":0,"name":"referee-response-27166","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.10882.r27167, Herbert H\u00f6nigsmann, Department of Dermatology, Division of Special & Environmental Dermatology, Medical University of Vienna, Vienna, Austria, 30 Oct 2017, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/6-1906\/v1#referee-response-27167","order":1,"name":"referee-response-27167","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author is in receipt of grants from the Chief Scientist\u2019s Office (Scottish government) and the British Skin Foundation.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}